Fresenius Settles With Johnson & Johnson to Market Stelara Alternative

By David Sachs

Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada.

Fresenius said Monday that the terms of the settlement for the drug, which mirrors Johnson & Johnson's trademarked Stelara, are confidential. Known as FYB202, the treatment also aids people with plaque psoriasis and ulcerative colitis, and is awaiting approval from regulators.

The settlement follows a similar one with Johnson & Johnson in the U.S. context. Fresenius Kabi and Formycon have had a license agreement in place since last year for marketing the drug after its approval, Fresenius said.

Johnson & Johnson did not immediately respond to a request for comment.

Write to David Sachs at [e-mail]

(END) Dow Jones Newswires

03-18-24 0551ET